The patents are valid through 2029 and 2030
Suven Life Sciences (Suven) has received one product patent from Eurasia (020506) and one product patent from Israel (220229) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2029 and 2030 respectively.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 14 granted patents from Eurasia and three granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
EP News Bureau – Mumbai